Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Medtronic and Scil Technology agree to partner for dental bone regeneration therapies

Medtronic : 29 April, 2008  (Company News)
Medtronic and Scil Technology have signed a development, licensing and supply agreement that focuses on development of Scil’s biologic rhGDF-5 (recombinant human Growth and Differentiating Factor 5) dental regenerative technology for use in bone regeneration for dental implant placement and treatment of periodontal disease.
Under this agreement, Scil Technology is primarily responsible for all research and development activities with Medtronic responsible for clinical trials, regulatory approvals and commercialisation.

These regenerative biologics may offer new approaches to saving teeth in patients who are at risk for tooth loss due to periodontal disease and provide new options for other dental procedures for the placement of dental implants. These therapies would be alternative treatments to the traditional bridging procedures performed by dentists.

The therapies derived from this partnership could enable Medtronic to impact the million or more patients each year who are being treated for periodontal disease or seeking dental restoration.

“The partnership with Scil Technology is a continuation of our strategy to expand our biologics portfolio” said Pete Wehrly, senior vice president and president of Medtronic’s Spinal and Biologics business. “Scil Technology’s therapies have the potential to offer our customers biologic solutions that will expand treatment options for their patients and offer new options for unmet needs in periodontal regeneration.”

This agreement strengthens Medtronic’s biologic portfolio and will be an important component to Medtronic both in the USA and internationally as the company continues its leadership in expanding indications for therapies utilizing biologics.

“Having completed a Phase I/II clinical trial of our dental regenerative material in Germany, the partnership with Medtronic further strengthens Scil Technology’s capability of bringing innovative products to the market. It also advances the company’s mission of improving the quality of patients’ lives,” said Dr Weishui Weiser, chief executive officer of Scil Technology.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo